Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
Executive Summary
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
You may also be interested in...
Joint Procurement Rising Up EU Agenda As Future Access Mechanism
Joint procurement is of growing interest in the EU as a means of providing access to expensive innovative medicines.
Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.